bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.
This channel curates preprints specific to quantitative methods in pre-clinical and clinical drug development, the approval and post-marketing phases, and clinical therapeutics. The papers can range in varying topics in this discipline:
- Clinical Pharmacology and Therapeutics (#cpt)
- Therapeutic Drug Monitoring (#tdm)
- Pharmacometrics (#phmx)
- Quantitative Systems Pharmacology (#qsp)
- Clinical Trial Design/Optimal Design (#ctd, #od)
- Pharmacoeconomics (#pec)
- Meta analyses (#metanal)
This list will grow over time. Please feel free to suggest new topics.
Instructions for authors (click here to view/hide)
Submit your paper to the Drug Development and Clinical Therapeutics bioRxiv channel:
- Submit your preprint to bioRxiv
- Use the tag '#ddct' at the very end of your abstract text.
- The tag '#ddct' can be followed by any of the other tags listed above under paper topics.
Please note the following expectations regarding papers in this channel:
- In the spirit of being a preprint and following open science principles, we encourage authors to submit detailed appendices of any code involved in developing quantitative models.
- Methodological and simulation based results must be 100% reproducible with the code provided by the authors.
- Application based models should have an appendix of the model code used to fit the data, project file (if the model is not code based), and an output file that contains: final parameter estimates, the variance-covariance matrix(ces) of random effects and variance-covariance matrix of the estimates if applicable. If a stochastic estimation method was used, please include posterior distribution samples of all parameters (or a reasonable parametric summary).
- Model code, parameters, and data, if not confidential, should be supplied as ASCII text or any other format that is generally readable with an open source software tool.
- All papers in this channel are subject to review by the open community using the discussion forums available for each topic.
- Authors, channel moderators and community members are allowed to use the social media options to market the preprint.
11 Articles
Channel RSS